Stocks · News reference
BioVie Announces Bezisterim Has Potential To Treat Parkinson's Disease; To Hold Talks With FDA Over Phase 3 Trial Design
BioVie Inc. (NASDAQ: BIVI) ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, today announced next stage of
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
What's Going On With BioVie Stock on Tuesday?
BioVie reported Phase 2 ADDRESS-LC trial results evaluating bezisterim for Long COVID, showing significant subgroup improvements.
BioVie shares are trading lower. The company announced topline results from Phase 2 ADDRESS‑LC trial evaluating Bezisterim for the treatment of neurological symptoms associated with long COVID.
Trading Halt: Halt status updated at 7:55:00 AM ET: Quotation Resumption: News and Resumption Times